Skip to main content

Advertisement

SpringerLink
Log in

Effect of Lactobacillus reuteri NCIMB 30351 drops on symptoms of infantile functional gastrointestinal disorders and gut microbiota in early infants: Results from a randomized, placebo-controlled clinical trial

  • RESEARCH
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Infantile functional gastrointestinal disorders, such as colic, constipation, diarrhea, and gastroesophageal reflux (regurgitation), often occur in early infancy and, representing one of the causes of significant parental anxiety, lead to a significant strain on the healthcare resources. In this study, we aimed to evaluate the effects of Lactobacillus reuteri drops (L. reuteri NCIMB 30351) on the symptoms of infantile colic, constipation, diarrhea, and gastroesophageal reflux, as well as on the levels of intestinal microbiota in full-term newborns during the first months of life. A randomized, placebo-controlled, single-masked (blinded), post-marketing clinical study was conducted in two clinical units—Children’s City Clinical Hospital of Moscow and Medical Center “St. Andrew’s Hospitals-NEBOLIT” from March 2020 to May 2022 in 90 infants aged from 1 to 4 months (mean age (± SD) 12.3 ± 5.09 weeks; 53.3% females, 46.7% males). Patients with colic, regurgitation (single symptom or combination of several symptoms), and constipation or diarrhea were randomly allocated in two parallel arms to receive either 5 drops (2 × 108 colony forming unit) of L. reuteri NCIMB 30351 (n = 60) or masked placebo (n = 30) for 25 consecutive days. Two treatment arms had equal numbers of patients with constipation and diarrhea (n = 30 each). Daily crying times and their duration, evacuations, and regurgitations were recorded in a structured diary. The levels of gut microbiota were analyzed by deep sequencing of bacterial 16S rRNA gene. Infants with colic receiving supplementary L. reuteri NCIMB 30351 for 25 days had significant reduction in the numbers of colic (change from baseline − 6.3 (7.34) vs − 3.0 (7.29) in placebo, P < 0.05) and numbers of crying cases and mean duration of crying (decrease from baseline − 144 (70.7) minutes, lower in the diarrhea subgroup than in constipation infants, compared with − 80 (58.9) in placebo, P < 0.0001), as well as regurgitation numbers (decreased by − 4.8 (2.49) with L. reuteri vs − 3 (7.74) with placebo). We also observed increased numbers of evacuations in infants with constipation (L. reuteri 2.2 (2.4) vs 0.9 (1.06) in placebo, P < 0.05). There was a remarkable reduction of evacuations in infants with diarrhea, while not statistically significant. The analysis of bacterial 16S rRNA gene in the collected samples showed that L. reuteri positively influences the proportions of prevalent species, while it negatively affects both conditionally pathogenic and commensal microbes. Additional in vitro test for formation of Clostridium colonies in the presence of the probiotic demonstrated that L. reuteri effectively inhibits the growth of pathogenic Clostridium species. No adverse events were reported in this study.

  Conclusion: The uptake of L. reuteri NCIMB 30351 leads to a significant reduction in the number of regurgitations, feeding-induced constipations, and diarrhea as well as mean daily numbers of crying and crying duration in infants during the first months of life. Our results suggest that L. reuteri NCIMB 30351 represents a safe and effective treatment for colic in newborns.

  Trial registration: ClinicalTrials.gov: NCT04262648.

What is Known:

• Infantile functional gastrointestinal disorders, such as colic, constipation, diarrhea, and gastroesophageal reflux (regurgitation), often occur in early infancy and, represent one of the causes of significant parental anxiety.

• A number of studies have shown that both the composition and diversity of the intestinal microbiota play important roles in the development and function of the gastrointestinal tract.

What is New:

• The uptake of L. reuteri NCIMB 30351 leads to a significant reduction in the number of regurgitations, feeding-induced constipations, and diarrhea as well as mean daily numbers of crying and crying duration in infants during the first months of life.

• L. reuteri positively influences the proportions of prevalent species, while it negatively affects both conditionally pathogenic and commensal microbes in gut microbiota.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data are available upon reasonable request.

References

  1. Lewis ML, Palsson OS, Whitehead WE, van Tilburg MAL (2016) Prevalence of functional gastrointestinal disorders in children and adolescents. J Pediatr 177:39–43.e3. https://doi.org/10.1016/j.jpeds.2016.04.008

    Article  PubMed  Google Scholar 

  2. Vernon-Roberts A, Alexander I, Day AS (2021) Systematic review of pediatric functional gastrointestinal disorders (Rome IV criteria). J Clin Med 10(21):5087. https://doi.org/10.3390/jcm10215087

    Article  PubMed  PubMed Central  Google Scholar 

  3. Backhed F, Roswall J, Peng Y et al (2015) Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17(5):690–703. https://doi.org/10.1016/j.chom.2015.04.004

    Article  CAS  PubMed  Google Scholar 

  4. Yassour M, Vatanen T, Siljander H et al (2016) Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med 8(343):343ra82. https://doi.org/10.1126/scitranslmed.aad0917

    Article  CAS  Google Scholar 

  5. Palmer C, Bik EM, DiGiulio DB et al (2007) Development of the human infant intestinal microbiota. PLoS Biol 5(7):e177. https://doi.org/10.1371/journal.pbio.0050177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, Avershina E, Rudi K, Narbad A, Jenmalm MC, Marchesi JR, Collado MC (2015) The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 26:26050. https://doi.org/10.3402/mehd.v26.26050. PMID: 25651996; PMCID: PMC4315782

    Article  PubMed  Google Scholar 

  7. Oozeer R, van Limpt K, Ludwig T et al (2013) Intestinal microbiology in early life: specific prebiotics can have similar functionalities as human-milk oligosaccharides. Am J Clin Nutr 98(2):561S–571S. https://doi.org/10.3945/ajcn.112.038893. Epub 2013 Jul 3

    Article  CAS  PubMed  Google Scholar 

  8. Bergstrom A, Skov TH, Bahl MI et al (2014) Establishment of intestinal microbiota during early life: a longitudinal, explorative study of a large cohort of Danish infants. Appl Environ Microbiol 80(9):2889–2900. https://doi.org/10.1128/AEM.00342-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ismail IH, Oppedisano F, Joseph SJ et al (2012) Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. Pediatr Allergy Immunol 23(7):674–681. https://doi.org/10.1111/j.1399-3038.2012.01328.x. Epub 2012 Jul 26

    Article  PubMed  Google Scholar 

  10. Kostic AD, Gevers D, Siljander H et al (2015) The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 17(2):260–273. https://doi.org/10.1016/j.chom.2015.01.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dogra S, Sakwinska O, Soh SE et al (2015) Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity. MBio 6(1):e02419–14. https://doi.org/10.1128/mBio.02419-14

    Article  PubMed  PubMed Central  Google Scholar 

  12. Penders J, Thijs C, Vink C et al (2006) Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 118(2):511–521. https://doi.org/10.1542/peds.2005-2824

    Article  PubMed  Google Scholar 

  13. Voreades N, Kozil A, Weir TL (2014) Diet and the development of the human intestinal microbiome. Front Microbiol 5:494. https://doi.org/10.3389/fmicb.2014.00494. eCollection 2014

    Article  PubMed  PubMed Central  Google Scholar 

  14. Koenig JE, Spor A, Scalfone N et al (2011) Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA 108(Suppl 1):4578–4585. https://doi.org/10.1073/pnas.1000081107. Epub 2010 Jul 28

    Article  PubMed  Google Scholar 

  15. Scholtens PA, Oozeer R, Martin R et al (2012) The early settlers: intestinal microbiology in early life. Annu Rev Food Sci Technol 3:425–447. https://doi.org/10.1146/annurev-food-022811-101120. Epub 2012 Jan 3

    Article  CAS  PubMed  Google Scholar 

  16. Stewart CJ, Ajami NJ, O’Brien JL et al (2018) Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature 562(7728):583–588. https://doi.org/10.1038/s41586-018-0617-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Milani C, Duranti S, Bottacini F et al (2017) The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev. 81(4):e00036–17. https://doi.org/10.1128/MMBR.00036-17

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sung V, Hiscock H, Tang ML et al (2014) Treating infant colic with the probiotic Lactobacillus reuteri: double-blind, placebo-controlled randomized trial. Pediatrics. 134(3):e562–9. https://doi.org/10.1136/bmj.g2107

    Article  Google Scholar 

  19. Indrio F, Di Mauro A, Riezzo G et al (2014) Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr 168(3):228–33. https://doi.org/10.1001/jamapediatrics.2013.4367

    Article  PubMed  Google Scholar 

  20. Savino F, Pelle E, Palumeri E et al (2007) Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 119(1):e124–30. https://doi.org/10.1542/peds.2006-1222

    Article  PubMed  Google Scholar 

  21. Savino F, Cordisco L et al (2010) Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 126(3):e526–e533. https://doi.org/10.1542/peds.2010-0433

    Article  PubMed  Google Scholar 

  22. Chau K, Lau E, Greenberg S et al (2015) Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 166(1):74–8. https://doi.org/10.1016/j.jpeds.2014.09.020

    Article  CAS  PubMed  Google Scholar 

  23. Sung V, D’Amico F, Cabana MD et al (2018) Lactobacillus reuteri to treat infant colic: a meta-analysis. Pediatrics 141(1):1–10. https://doi.org/10.1542/peds.2017-1811

    Article  Google Scholar 

  24. Gutiérrez-Castrellón P, Indrio F, Bolio-Galvis A, Jiménez-Gutiérrez C, Jimenez-Escobar I, López-Velázquez G (2017) Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: Systematic review with network metaanalysis. Medicine (Baltimore) 96(51):375. https://doi.org/10.1097/MD.0000000000009375. Erratum in: Medicine (Baltimore). 2018 Jan;97(4):e9730. PMID: 29390535; PMCID: PMC5758237

    Article  Google Scholar 

  25. Partty A, Kalliomaki M, Salminen S et al (2017) Infantile colic is associated with low-grade systemic inflammation. J Pediatr Gastroenterol Nutr 64(5):691–5. https://doi.org/10.1097/MPG.0000000000001340

    Article  PubMed  Google Scholar 

  26. Schulz KF, Altman DG, Moher D; CONSORT Group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332. https://doi.org/10.1136/bmj.c332. PMID: 20332509; PMCID: PMC2844940

    Article  Google Scholar 

  27. Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB (2013) Designing clinical research, 4th edn. Lippincott Williams and Wilkins, Philadelphia, PA. ISBN 9781608318049

    Google Scholar 

  28. Chow S-C, Shao J, Wang H, Lokhnygina Y (2017) Sample size calculations in clinical research, 3rd ed. Chapman and Hall/CRC, New York. https://doi.org/10.1201/9781315183084. eBook ISBN 9781315183084

  29. Anderson MJ (2001) A new method for non-parametric multivariate analysis of variance. Austral Ecol 26:32–46. https://doi.org/10.1111/j.1442-9993.2001.01070.pp.x

    Article  Google Scholar 

  30. Efimova D, Tyakht A, Popenko A, Vasilyev A, Altukhov I, Dovidchenko N et al (2018) Knomics-Biota system for exploratory analysis of human gut microbiota data. BioData Min 11:25

    Article  PubMed  PubMed Central  Google Scholar 

  31. Odintsova VE, Klimenko NS, Tyakht AV (2022) Approximation of a microbiome composition shift by a change in a single balance between two groups of Taxa. mSystems 7(3):e0015522. https://doi.org/10.1128/msystems.00155-22. Epub 2022 May 9. PMID: 35532211; PMCID: PMC9239069

Download references

Funding

This study was funded by Novo Natum LLC.

Author information

Authors and Affiliations

  1. Novo Natum LLC, Moscow, Russia

    Oleg Yu Tyrsin, Dmitry Yu Tyrsin, Daniil G. Nemenov, Alexey S. Ruzov, Vera E. Odintsova, Stanislav I. Koshechkin & Luciano D`Amico

Authors
  1. Oleg Yu Tyrsin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dmitry Yu Tyrsin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniil G. Nemenov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexey S. Ruzov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vera E. Odintsova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stanislav I. Koshechkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luciano D`Amico
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Daniil Nemenov and Alexey Ruzov wrote the main manuscript text. In the meanwhile, Koshechkin Stanislav I made all the tabulation and figures. Odintsova Vera E, D’Amico Luciano, Tyrsin Dmitry Yu, and Tyrsin Oleg Yu also contributed towards the analysis and compilation of the manuscript. All authors reviewed the manuscript.

Corresponding author

Correspondence to Luciano D`Amico.

Ethics declarations

Ethics approval

The research was conducted in accordance with the Declaration of Helsinki (Fortaleza, 2013) and ICH guideline for good clinical practice E6(R2).

Conflict of interest

The authors declare no competing interests.

Additional information

Communicated by Peter de Winter

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tyrsin, O.Y., Tyrsin, D.Y., Nemenov, D.G. et al. Effect of Lactobacillus reuteri NCIMB 30351 drops on symptoms of infantile functional gastrointestinal disorders and gut microbiota in early infants: Results from a randomized, placebo-controlled clinical trial. Eur J Pediatr 183, 2311–2324 (2024). https://doi.org/10.1007/s00431-024-05473-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-024-05473-y

Keywords

Search

Navigation